CILP: A Potential Drug Target and Biomarker for Osteoarthritis

Target Name: CILP

NCBI ID: G8483

CILP

CILP: A Potential Drug Target and Biomarker for Osteoarthritis

CILP, or Cartilage Intermediate Layer Protein 1, is a protein that is expressed in the cartilage tissue and is known for its role in the production and maintenance of cartilage. CILP has been identified as a potential drug target and has been shown to play a role in the development and progression of various inflammatory and degenerative conditions, including osteoarthritis and rheumatoid arthritis.

The discovery and characterization of CILP comes from a study by a research group led by Dr. Xujiong Ye at the Institute of Joint Research, Capital Medical University, Beijing, China. The study, published in the journal Biochimica et Biophysica Acta (BBA) - Matrix Biology and Disease Sciences in 2018, found that CILP was expressed in the cartilage tissue and was involved in the production and maintenance of cartilage extracellular matrix (ECM).

The authors also showed that overexpression of CILP in mouse models of osteoarthritis led to increased joint inflammation, pain, and functional decline, while inhibition of CILP reduced these symptoms. The results of the study suggested that CILP may be a potential drug target for the treatment of osteoarthritis.

In addition to its potential use as a drug target, CILP has also been identified as a potential biomarker for the diagnosis and monitoring of osteoarthritis. The authors showed that increasing the expression of CILP in mouse models of osteoarthritis led to increased joint inflammation, pain, and functional decline, while inhibition of CILP reduced these symptoms. This suggests that CILP may be a useful biomarker for the diagnosis and monitoring of osteoarthritis.

The role of CILP in the development and progression of osteoarthritis and other inflammatory and degenerative conditions is still being studied. However, the potential use of CILP as a drug target and biomarker makes it an important area of research for the development of new treatments for these conditions.

In conclusion, CILP is a protein that is expressed in the cartilage tissue and is involved in the production and maintenance of cartilage ECM. The potential use of CILP as a drug target and biomarker makes it an important area of research for the development of new treatments for osteoarthritis and other inflammatory and degenerative conditions. Further studies are needed to fully understand the role of CILP in these conditions and to develop effective treatments.

Protein Name: Cartilage Intermediate Layer Protein

Functions: Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage

The "CILP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CILP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets